Register
Clinical News
eMediNexus Coverage from: 
A new treatment for osteoporosis in postmenopausal women at high risk of fracture
eMediNexus,  11 April 2019
remove_red_eye 622 Views
#Obstetrics and Gynecology #Orthopedics #Pharmacist #Rheumatology

0 Read Comments                

The US Food and Drug Administration (FDA) has approved Evenity (romosozumab-aqqg) to treat osteoporosis in postmenopausal women at high risk of breaking a bone (fracture). These are women with a history of osteoporotic fracture or multiple risk factors for fracture, or those who have failed or are intolerant to other osteoporosis therapies.
Read the full story.
Create a free account.
Sign Up to instantly read 30000+ free Articles & 1000+ Case Studies
Create Account

Already registered?

Login Now